Equities research analysts expect that West Pharmaceutical Services Inc. (NYSE:WST) will post earnings per share of $0.72 for the current quarter, Zacks reports. Three analysts have issued estimates for West Pharmaceutical Services’ earnings. The highest EPS estimate is $0.72 and the lowest is $0.71. West Pharmaceutical Services posted earnings of $0.70 per share in the same quarter last year, which suggests a positive year over year growth rate of 2.9%. The firm is expected to announce its next quarterly earnings results on Thursday, July 25th.
According to Zacks, analysts expect that West Pharmaceutical Services will report full year earnings of $2.88 per share for the current financial year, with EPS estimates ranging from $2.86 to $2.90. For the next financial year, analysts forecast that the firm will post earnings of $3.28 per share, with EPS estimates ranging from $3.24 to $3.35. Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for West Pharmaceutical Services.
West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings data on Thursday, April 25th. The medical instruments supplier reported $0.74 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.66 by $0.08. West Pharmaceutical Services had a return on equity of 16.38% and a net margin of 12.53%. The firm had revenue of $443.50 million during the quarter, compared to the consensus estimate of $431.00 million. During the same quarter in the previous year, the company posted $0.62 EPS. The business’s revenue for the quarter was up 6.7% compared to the same quarter last year.
Several equities analysts have issued reports on the company. Zacks Investment Research downgraded Inflarx from a “buy” rating to a “hold” rating in a research report on Friday, May 3rd. William Blair reiterated an “outperform” rating on shares of bluebird bio in a research report on Tuesday, April 23rd. Finally, Jefferies Financial Group lifted their price objective on EXACT Sciences from $100.00 to $115.00 and gave the company a “buy” rating in a research report on Wednesday, May 1st.
In other news, VP Daniel Malone sold 4,458 shares of West Pharmaceutical Services stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $123.03, for a total value of $548,467.74. Following the completion of the sale, the vice president now directly owns 33,478 shares of the company’s stock, valued at approximately $4,118,798.34. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 1.70% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Advisors Asset Management Inc. grew its position in West Pharmaceutical Services by 13.4% in the fourth quarter. Advisors Asset Management Inc. now owns 13,612 shares of the medical instruments supplier’s stock valued at $1,334,000 after acquiring an additional 1,604 shares during the period. Cambridge Investment Research Advisors Inc. increased its holdings in shares of West Pharmaceutical Services by 13.1% in the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 3,306 shares of the medical instruments supplier’s stock worth $324,000 after acquiring an additional 382 shares in the last quarter. Mackenzie Financial Corp increased its holdings in shares of West Pharmaceutical Services by 10.2% in the fourth quarter. Mackenzie Financial Corp now owns 2,455 shares of the medical instruments supplier’s stock worth $241,000 after acquiring an additional 228 shares in the last quarter. LPL Financial LLC increased its holdings in shares of West Pharmaceutical Services by 13.8% in the fourth quarter. LPL Financial LLC now owns 14,829 shares of the medical instruments supplier’s stock worth $1,454,000 after acquiring an additional 1,802 shares in the last quarter. Finally, PNC Financial Services Group Inc. increased its holdings in shares of West Pharmaceutical Services by 0.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 23,952 shares of the medical instruments supplier’s stock worth $2,349,000 after acquiring an additional 173 shares in the last quarter. 91.90% of the stock is owned by institutional investors.
WST traded up $0.07 during trading on Thursday, hitting $123.91. The company’s stock had a trading volume of 51,717 shares, compared to its average volume of 375,230. The company’s 50 day moving average price is $120.33. The company has a quick ratio of 2.13, a current ratio of 2.88 and a debt-to-equity ratio of 0.19. West Pharmaceutical Services has a 12 month low of $91.75 and a 12 month high of $127.06. The company has a market capitalization of $9.10 billion, a PE ratio of 44.10, a price-to-earnings-growth ratio of 3.76 and a beta of 1.30.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, August 7th. Stockholders of record on Wednesday, July 24th will be paid a $0.15 dividend. The ex-dividend date is Tuesday, July 23rd. This represents a $0.60 annualized dividend and a dividend yield of 0.48%. West Pharmaceutical Services’s dividend payout ratio (DPR) is currently 21.35%.
About West Pharmaceutical Services
West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, South Korea, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.
Further Reading: Why are analyst ratings important in trading stocks?
Get a free copy of the Zacks research report on West Pharmaceutical Services (WST)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.